Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Celiac Disease Therapeutics Report 2016: Pipeline Review of 12 Companies & 21 Drug Molecules - Research and Markets

Research and Markets
Posted on: 17 Oct 16

Research and Markets has announced the addition of the "Celiac Disease - Pipeline Review, H2 2016" report to their offering.

Celiac Disease pipeline therapeutics constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by Companies and remaining by the Universities Institutes. Our latest report Celiac Disease - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Celiac Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Celiac Disease Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren's syndrome and Turner syndrome.

Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 8 and 6 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecule, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Macrophage Migration Inhibitory Factor Overview
  3. Therapeutics Development
  4. Pipeline Products for Macrophage Migration Inhibitory Factor - Overview
  5. Pipeline Products for Macrophage Migration Inhibitory Factor - Comparative Analysis
  6. Macrophage Migration Inhibitory Factor - Therapeutics under Development by Companies
  7. Macrophage Migration Inhibitory Factor - Therapeutics under Investigation by Universities/Institutes
  8. Macrophage Migration Inhibitory Factor Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Macrophage Migration Inhibitory Factor - Products under Development by Companies
  13. Macrophage Migration Inhibitory Factor - Products under Investigation by Universities/Institutes
  14. Macrophage Migration Inhibitory Factor - Companies Involved in Therapeutics Development
  • Amgen Inc.
  • Amyra Biotech AG
  • Avaxia Biologics, Inc.
  • Calypso Biotech SA
  • enGene, Inc
  • F. Hoffmann-La Roche Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • ImmusanT, Inc.
  • Innovate Biopharmaceuticals, Inc.
  • Intrexon Corporation
  • Sanofi
  • Zedira GmbH

For more information about this report visit

View source version on

Business Wire

Last updated on: 17/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.